Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases

Condition(s) studied

Investigational drug(s) / intervention(s)

T cell injection targeting CD7 chimeric antigen receptor: Subjects who sign the informed consent form and meet the inclusion/exclusion criteria will be entered into the 0.25×108, 1×108 and 2×108 CAR-T groups, in order of priority, and will be administered 1 dose of

Study summary

The primary objective was to evaluate the safety of CD7 CAR-T cells for the treatment of subjects with relapsed/refractory AID. CD7 CAR-T cells were infused in a single infusion in subjects who were screened after signing an informed consent form and undergoing single nucleus cell collection and pretreatment, and blood was collected before and after the infusion for pharmacokinetic, pharmacodynamic, immunogenicity, and safety evaluations.

Eligibility

Primary outcome measure(s)

• adverse events — About 1 year
  Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

Trial sites (1)

More PersonGen BioTherapeutics (Suzhou) Co., Ltd. trials in China